Urgo Medical UK & Ireland

Name

Urgo Medical UK & Ireland

Legal name

Urgo Limited

Website

https://urgo.co.uk

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Advanced Wound Care Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro industry

PRIMARYHLAHALAE

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

SECONDARYHLAAAGAG

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYHLAHAMAH

Compression Therapy & Lymphedema DME (Garments, Pneumatic Pumps)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)

Keywords

• Advanced wound care
• Medical device dressings
• Chronic wound management
• Diabetic foot ulcer treatment
• Compression therapy products

Headquarters

HQ city

Shepshed, Loughborough

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Wound Care Product Sales: Urgo Medical generates revenue through the sale of advanced wound care dressings and medical devices. Products are sold to healthcare professionals and institutions (NHS, hospitals, clinics) as well as indirectly to patients. The portfolio includes multiple product families: UrgoTul range (TLC dressings), UrgoStart Plus range (TLC-NOSF dressings), UrgoClean, UrgoKTwo compression, and UrgoTul Ag silver dressings. Revenue is derived from product sales to healthcare systems and providers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Urgo Medical UK & Ireland manufactures and distributes advanced wound care dressings and medical devices for the treatment of acute and chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, burns, surgical wounds, and skin tears. The portfolio is built on proprietary TLC (Technology Lipido-Colloid) and TLC-NOSF (Nano-OligoSaccharide Factor) healing matrix technologies, supported by clinical evidence covering more than 54,000 patients and recommended by NICE and IWGDF international guidelines. Products are sold directly to NHS hospitals, community care providers, and private healthcare institutions across the UK and Ireland.

Product overview

Urgo Medical UK & Ireland is the advanced wound care division of Urgo Group, offering a portfolio of clinically-proven wound care products built on proprietary technology platforms. The portfolio centres on two core technology families: the TLC (Technology Lipido-Colloid) healing matrix platform — used in the UrgoTul Range (UrgoTul, UrgoTul Absorb, UrgoTul Absorb Border, UrgoTul Absorb Heel, UrgoTul Ag) — and the advanced TLC-NOSF (Nano-OligoSaccharide Factor) healing matrix used in the UrgoStart Plus Range (UrgoStart Plus Border, UrgoStart Plus Pad, UrgoStart Contact Layer). Supporting these are UrgoClean and UrgoClean Rope for wound bed preparation through desloughing, and compression products (UrgoKTwo, UrgoKTwo Reduced, Urgo Compression Hosiery) used as adjuncts in venous leg ulcer management. Together, the products cover the full wound healing pathway from desloughing and cleansing through to granulation, epithelialisation, and compression therapy, treating conditions including leg ulcers, diabetic foot ulcers, pressure ulcers, burns, surgical wounds, and skin tears.

Differentiator

Problem solved

Functional benefit

Brands

• UrgoStart Plus Range: Advanced wound care treatment range with TLC-NOSF healing matrix for diabetic foot ulcers and venous leg ulcers
• UrgoTul Range
• UrgoTul Ag
• UrgoClean
• UrgoKTwo
• Urgo Compression Hosiery

Products and services

• UrgoStart Plus Range A range of advanced wound care dressings using TLC-NOSF (Technology Lipido-Colloid – Nano-OligoSaccharide Factor) healing matrix and poly-absorbent fibres, designed to close chronic wounds sooner by reducing excess matrix metalloproteinases (MMPs) and continuously cleaning the wound. NICE-recommended for diabetic foot ulcers and venous leg ulcers.
• UrgoTul Range A family of wound dressings featuring Technology Lipido-Colloid (TLC) healing matrix. Provides and maintains a moist wound healing environment, stimulates fibroblast proliferation, and ensures pain-free, atraumatic removal. Accredited by the British Skin Foundation.
• UrgoTul Ag Non-adherent conformable wound dressing with TLC-Ag silver healing matrix. Combats local infection through quick and effective reduction of bacterial load, indicated for wounds at risk of infection or showing signs of local infection.
• UrgoClean Fibrous wound dressing that safely and effectively removes slough and debris from the wound bed to prepare for healing. Traps slough, absorbs exudate, protects peri-wound skin, and enables atraumatic, painless removal. Indicated for exuding wounds in the desloughing phase.
• UrgoClean Rope Cavity version of UrgoClean, used for the treatment of cavity wounds. Provides the same desloughing and exudate management capabilities in cavity wound applications.
• UrgoKTwo and UrgoKTwo Reduced Compression bandage system for venous leg ulcers, also available in latex-free variant. Provides graduated compression as part of a comprehensive wound management approach.
• Urgo Compression Hosiery Compression hosiery products for the management of venous conditions and as part of leg ulcer treatment protocols.

Quantifiable outcome

• 60% more patients healed compared to neutral dressing (Lancet Diabetes & Endocrinology, EXPLORER RCT, 2018)
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Mölnlycke Health Care: Swedish wound care specialist behind Mepilex, Mepitel, and Avance negative pressure systems. Direct competitor in advanced foam and silicone dressings across NHS hospitals, with comparable clinical evidence strategy.
• ConvaTec: UK-headquartered advanced wound care and ostomy company with Aquacel, Foam Lite, and DuoDERM product lines. Competes directly with Urgo in chronic wound management and shares NHS-focused go-to-market.
• Smith & Nephew: Global advanced wound care leader (e.g., Allevyn, PICO negative pressure wound therapy) competing head-to-head with Urgo in NHS and international advanced wound dressing markets. Directly comparable on product category, customer base (wound care nurses, hospitals), and evidence-led sales motion.
• Coloplast: Danish medtech company with Biatain and Comfeel wound care ranges. Directly comparable in advanced wound dressings sold via NHS Supply Chain and community care, with similar clinical education sales motion.
• Integra LifeSciences (Derma Sciences): US-listed medtech with strong wound care portfolio including Integra Dermal Regeneration Template and Medihoney. Compares to Urgo on advanced/regenerative wound healing technology for chronic and complex wounds.
• Hartmann Group: German medical products company with wound care brands including Cosmopor, Hydrocoll, and Zetuvit. Competes with Urgo across European NHS-equivalent systems on advanced and traditional wound dressings.
• Lohmann & Rauscher: European wound care and compression specialist (Vliwasoft, Cellacare, Rosidal). Comparable on compression therapy products (UrgoKTwo vs. Rosidal) and competes across UK and European advanced wound dressings markets.

Emerging players

• Organogenesis: US regenerative medicine company with wound care biologics (Apligraf, Dermagraft) competing with Urgo's TLC-NOSF matrix at the advanced/biological end of chronic wound management. Comparable clinical evidence strategy in diabetic foot ulcers.

Broad incumbents

• 3M Health Care (Solventum / KCI): Global medical device conglomerate whose KCI division leads in negative pressure wound therapy (V.A.C.) and now Solventum sells advanced wound dressings. Competes with Urgo in NHS wound care with much broader medtech portfolio and scale.
• B. Braun: Global medical device and pharmaceutical company with wound care products (Askina, Cuticell) sold through NHS and international channels. Larger, diversified incumbent with comparable hospital GTM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCTPoq7Ioqdp6id0PuCv5WmQ?view_as=subscriber
• LinkedInlinkedin.com/company/urgo-medical-uk-ie

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Urgo Medical UK & Ireland